Biogen
Executive Summary
Phase I clinical trials for interleukin 2 product, Bioleukin, will begin "in a few days," the firm said May 22 at an Alex Brown health care seminar. Shionogi will conduct trials in Japan. The company also said it is about to begin clinical trials for rDNA-derived hepatitis B vaccine in Europe.